Brought to you by 
Illumina acquires DNA sequencer Pacific Bio; deal terminated
03 Jan 2020
Executive Summary
Illumina Inc. acquired "long-read" DNA sequencing company Pacific Biosciences of California Inc. for $8 per share in cash (89% premium to the prior 10-day trading average), or a fully diluted equity value of $1.2bn (taking into account cash and debt enterprise value of $1.1bn; sales multiple of 12.7x) .
Deal Industry
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Illumina acquires DNA sequencer Pacific Bio; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice